Cardioprotection of 17β-estradiol against hypoxia/reoxygenation in cardiomyocytes is partly through up-regulation of CRH receptor type 2

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 17-25

  Cong, Binhai ^a   Xu, Yongjun ^a   Sheng, Hui ^a   Zhu, Xiaoyan ^a   Wang, Long ^a   Zhao, Wei ^a   Tang, Zhiping ^b   Lu, Jianqiang ^b   Ni, Xin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF SPORT   (China)

Author keywords

Cardiomyocytes; Corticotropin releasing hormone receptor type 2; Estrogens; Hypoxia reoxygenation; Specific protein1; Urocortins

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; LACTATE DEHYDROGENASE; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; UROCORTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENE SILENCING; HEART MUSCLE; HEART PROTECTION; HORMONE ACTION; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR UPREGULATION; REOXYGENATION; RNA INTERFERENCE;

17Β-ESTRADIOL; CARDIOMYOCYTES; CORTICOTROPHIN-RELEASING HORMONE RECEPTOR TYPE 2; CORTICOTROPIN-RELEASING HORMONE RECEPTOR TYPE 2; CRHR2; E2; ER; ERES; ESTROGEN RECEPTOR; ESTROGEN RESPONSES ELEMENTS; ESTROGENS; H/R; HYPOXIA/REOXYGENATION; IHD; IPC; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; LACTATE DEHYDROGENASE; LDH; METHYL THIAZOLYL TETRAZOLIUM; MTT; RADIOIMMUNOASSAY; RIA; SIRNA; SMALL INTERFERING RNA; SP1; SPECIFIC PROTEIN 1; SPECIFIC PROTEIN1; UCN; UROCORTIN; UROCORTINS;

ANIMALS; CARDIOTONIC AGENTS; CELL HYPOXIA; DOWN-REGULATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE KNOCKDOWN TECHNIQUES; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; OVARIECTOMY; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SP1 TRANSCRIPTION FACTOR; UP-REGULATION; UROCORTINS;

EID: 84884540127     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.09.002     Document Type: Article

References (43)

1. Arias-Loza P.A., Kreissl M.C., Kneitz S., Kaiser F.R., Israel I., Hu K., Frantz S., Bayer B., Fritzemeier K.H., Korach K.S., Pelzer T. The estrogen receptor-α is required and sufficient to maintain physiological glucose uptake in the mouse heart. Hypertension 2012, 60(4):1070-1077.
2. Barrett-Connor E., Bush T.L. Estrogen and coronary heart disease in women. JAMA 1991, 265:1861-1867.
3. Batistuzzo D.M., Krey G., Hihi A.K., Wahli W. Functional interaction between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 promoter. J. Biol. Chem. 1997, 272:18250-18260.
4. Brar B.K., Stephanou A., Okosi A., Lawrence K.M., Knight R.A., Marber M.S., Latchman D.S. CRH-like peptides protect cardiac myocytes from lethal ischemic injury. Mol. Cell Endocrinol. 1999, 158:55-63.
5. Brar B.K., Jonassen A.K., Stephanou A., Santilli G., Railson J., Knight R.A., Yellon D.M., Latchman D.S. UCN protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J. Biol. Chem. 2000, 275:8508-8514.
6. Brar B.K., Stephanou A., Knight R., Latchman D.S. Activation of protein kinase B/Akt by UCN is essential for its ability to protect cardiomyocytess against hypoxia/reoxygenation-induced cell death. J. Mol. Cell. Cardiol. 2002, 34:483-492.
7. Calderón-Sánchez E.M., Ruiz-Hurtado G., Smani T., Delgado C., Benitah J.P., Gómez A.M., Ordóñez A. Cardioprotective action of urocortin in postconditioning involves recovery of intracellular calcium handling. Cell Calcium 2011, 50(1):84-90.
8. Catalano R.D., Kyriakou T., Chen J., Easton A., Hillhouse E.W. Regulation of corticotropin-releasing hormone type 2 receptors by multiple promoters and alternative splicing: identification of multiple splice variants. Mol. Endocrinol. 2003, 17(3):395-410.
9. Coste S.C., Heldwein K.A., Stevens S.L., Tobar-Dupres E., Stenzel-Poore M.P. IL-1alpha and TNF alpha down-regulate CRH receptor-2 mRNA expression in the mouse heart. Endocrinology 2001, 142(8):3537-3545.
10. Cowley S.M., Hoare S., Mosselman S., Parker M.G. Estrogen receptors alpha and beta form heterodimers on DNA. J. Biol. Chem. 1997, 272:19858-19862.
11. Davis M.E., Pemberton C.J., Yandle T.G., Lainchbury J.G., Rademaker M.T., Nicholls M.G., Frampton C.M., Richards A.M. Urocortin-1 infusion in normal humans. J. Clin. Endocrinol. Metab. 2004, 89(3):1402-1409.
12. Davis M.E., Pemberton C.J., Yandle T.G., Lainchbury J.G., Rademaker M.T., Nicholls M.G., Frampton C.M., Richards A.M. Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. Clin. Sci. 2005, 109(4):381-388.
13. Emeto T.I., Moxon J.V., Rush C., Woodward L., Golledge J. Relevance of urocortins to cardiovascular disease. J. Mol. Cell Cardiol. 2011, 51(3):299-307.
14. Gomez L.A., Alekseev A.E., Aleksandrova L.A., Brady P.A., Terzic A. Use of the MTT assay in adult ventricular cardiomyocytes to assess viability: effects of adenosine and potassium on cellular survival. J. Mol. Cell Cardiol. 1997, 29:1255-1266.
15. Grady D., Herrington D., Bittner V., Blumenthal R., Davidson M., Hlatky M., Hsia J., Hulley S., Herd A., Khan S., Newby L.K., Waters D., Vittinghoff E., Wenger N. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002, 288:49-57.
16. Grohé C., Kahlert S., Löbbert K., Stimpel M., Karas R.H., Vetter H., Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 1997, 416:107-112.
17. Haeger P., Andrés M.E., Forray M.I., Daza C., Araneda S., Gysling K. Estrogen receptors alpha and beta differentially regulated the transcriptional activity of the UCN gene. J. Neurosci. 2006, 26(18):4908-4916.
18. Hodis H.N., Mack W.J., Azen S.P., Lobo R.A., Shoupe D., Mahrer P.R., Faxon D.P., Cashin-Hemphill L., Sanmarco M.E., French W.J., Shook T.L., Gaarder T.D., Mehra A.O., Rabbani R., Sevanian A., Shil A.B., Torres M., Vogelbach K.H., Selzer R.H. Women's estrogen-progestin lipid-lowering hormone atherosclerosis regression trial research group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med. 2003, 349:535-545.
19. Ikeda K., Fujioka K., Manome Y., Tojo K. Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease. Int. J. Endocrinol. 2012, 2012:198628.
20. Jeanes H.L., Tabor C., Black D., Ederveen A., Gray G.A. Oestrogen-mediated cardioprotection following ischaemia and reperfusion is mimicked by an oestrogen receptor (ER)α agonist and unaffected by an ERβ antagonist. J. Endocrinol. 2008, 197:493-501.
21. Klein-Hitpass L., Schorrp M., Wagner U., Ryffel G.U. An estrogen-responsive element derived from the 59 flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 1986, 46:1053-1061.
22. Knight R.A., Chen-Scarabelli C., Yuan Z., McCauley R.B., Di Rezze J., Scarabelli G.M., Townsend P.A., Latchman D., Saravolatz L., Faggian G., Mazzucco A., Chowdrey H.S., Stephanou A., Scarabelli T.M. Cardiac release of UCN precedes the occurrence of irreversible myocardial damage in the rat heart exposed to I/R injury. FEBS Lett. 2008, 582(6):984-990.
23. Knowlton A.A., Lee A.R. Estrogen and the cardiovascular system. Pharmacol. Ther. 2012, 135(1):54-70.
24. Liu H., Pedram A., Kim J.K. Oestrogen prevents cardiomyocyte apoptosis by suppressing p38α-mediated activation of p53 and by down-regulating p53 inhibition on p38β. Cardiovasc. Res. 2011, 89:119-128.
25. Mendelsohn M., Karas R. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 1999, 340(23):1801-1811.
26. Mendelsohn M., Karas R. Molecular and cellular basis of cardiovascular gender differences. Science 2005, 308:1583-1586.
27. Murphy E. Estrogen signaling and cardiovascular disease. Circ. Res. 2011, 109(6):687-696.
28. Nikolic I., Liu D., Bell J., Collins J., Steenbergen C., Murphy E. Treatment with an estrogen receptor β selective agonist is cardioprotective. J. Mol. Cell Cardiol. 2007, 42:769-780.
29. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277:1508-1510.
30. Patten R.D., Pourati I., Aronovitz M.J., Baur J., Celestin F., Chen X., Michael A., Haq S., Nuedling S., Grohe C., Force T., Mendelsohn M.E., Karas R.H. 17β-Estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ. Res. 2004, 95:692-699.
31. Pedram A., Razandi M., Aitkenhead M., Hughes C.C., Levin E.R. Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology. J. Biol. Chem 2002, 277(52):50768-50775.
32. Pelzer T., Loza P.A., Hu K., Bayer B., Dienesch C., Calvillo L., Couse J.F., Korach K.S., Neyses L., Ertl G. Increased mortality and aggravation of heart failure in estrogen receptor β knockout mice after myocardial infarction. Circulation 2005, 111:1492-1498.
33. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307(5715):1625-1630.
34. Ropero A.B., Eghbali M., Minosyan T.Y., Tang G., Toro L., Stefani E. Heart estrogen receptor alpha: distinct membrane and nuclear distribution patterns and regulation by estrogen. J. Mol. Cell Cardiol. 2006, 41(3):496-510.
35. Schuit S.C., Oei H.H., Witteman J.C., Geurts van Kessel C.H., van Meurs J.B., Nijhuis R.L., van Leeuwen J.P., de Jong F.H., Zillikens M.C., Hofman A., Pols H.A., Uitterlinden A.G. Estrogen receptor α gene polymorphisms and risk of myocardial infarction. JAMA 2004, 291:2969-2977.
36. Shinmura K., Nagai M., Tamaki K., Bolli R. Loss of ischaemic preconditioning in ovariectomized rat hearts: possible involvement of impaired protein kinase C epsilon phosphorylation. Cardiovasc. Res. 2008, 79(3):387-394.
37. Shinohara T., Takahashi N., Ooie T., Ichinose M., Hara M., Yonemochi H. Estrogen inhibits hyperthermia-induced expression of heat-shock protein 72 and cardioprotection against hypoxia/reperfusion injury in female rat heart. J. Mol. Cell Cardiol. 2004, 37:1053-1061.
38. Shlipak M.G., Angeja B.G., Go A.S., Frederick P.D., Canto J.G., Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001, 104:2300-2304.
39. Smani T., Calderón-Sanchez E., Gómez-Hurtado N., Fernández-Velasco M., Cachofeiro V., Lahera V., Ordoñez A., Delgado C. Mechanisms underlying the activation of L-type calcium channels by urocortin in rat ventricular myocytes. Cardiovasc. Res. 2010, 87(3):459-466.
40. 3K/ERK1/2 and lysosomal degradation pathway and contributes to EPC proliferation. Int. J. Cardiol. 2012, 158(1):46-53.
41. Townsend P.A., Davidson S.M., Clarke S.J., Khaliulin I., Carroll C.J., Scarabelli T.M., Knight R.A., Stephanou A., Latchman D.S., Halestrap A.P. Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:928-938.
42. Wang M., Crisostomo P., Wairiuko G.M., Meldrum D.R. Estrogen receptor-α mediates acute myocardial protection in females. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:2204-2209.
43. Wang S., Zhu X., Cong B., You X., Wang Y., Wang W., Ni X. Estrogenic action on arterial smooth muscle: permissive for maintenance of CRHR2 expression. Endocrinology 2012, 153(4):1915-1924.